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SUMMARY
Background—Idiosyncratic drug-induced liver injury (DILI) is a complex disorder that is
difficult to predict, diagnose and treat.
Aim—To describe the global serum proteome of patients with DILI and controls.
Methods—A label-free, mass spectrometry-based quantitative proteomic approach was used to
explore protein expression in serum samples from 74 DILI patients (collected within 14 days of
DILI onset) and 40 controls. A longitudinal analysis was conducted in a subset of 21 DILI patients
with available 6-month follow-up serum samples.
Results—Comparison of DILI patients based on pattern, severity and causality assessment of
liver injury revealed many differentially expressed priority 1 proteins among groups. Expression
of fumarylacetoacetase was correlated with alanine aminotransferase (ALT; r = 0.237; P = 0.047),
aspartate aminotransferase (AST; r = 0.389; P = 0.001) and alkaline phosphatase (r = −0.240; P =
0.043), and this was the only protein with significant differential expression when comparing
patients with hepatocellular vs. cholestatic or mixed injury. In the longitudinal analysis, expression
of 53 priority 1 proteins changed significantly from onset of DILI to 6-month follow-up, and
nearly all proteins returned to expression levels comparable to control subjects. Ninety-two serum
priority 1 proteins with significant differential expression were identified when comparing the
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DILI and control groups. Pattern analysis revealed proteins that are components of inflammation,
immune system activation and several hepatotoxicity-specific pathways. Apolipoprotein E
expression had the greatest power to differentiate DILI patients from controls (89% correct
classification; AUROC = 0.97).
Conclusion—This proteomic analysis identified differentially expressed proteins that are
components of pathways previously implicated in the pathogenesis of idiosyncratic drug-induced
liver injury.
INTRODUCTION
Although relatively rare with the majority of approved medications, idiosyncratic drug-
induced liver injury (DILI) is an increasingly common event due to ever-expanding use of
prescription medications. DILI is the most frequent adverse drug reaction that results in
termination of new drug development programmes, failure of approval by regulatory
agencies, or withdrawal of approved medications.1–4 When idiosyncratic DILI does occur it
can be a serious clinical event and, in fact, accounts for up to 13% of acute liver failure
cases in the United States.5–7 Despite the large impact DILI has on both patient health and
the development of important new medications, there is little understanding of the risk
factors and pathogenesis of idiosyncratic ADRs that result in liver injury.8, 9 This lack of
understanding has prevented development of new clinical tests that are needed to aid in
diagnosis and management of DILI.
Worldwide, several multicenter networks have been established to aid in the study of
identification, causes and prevention of idiosyncratic DILI. In the United States, the Drug-
Induced Liver Injury Network (DILIN) was founded in 2003 as a collaborative effort among
the National Institutes of Health, eight academic clinical centres, and a data coordinating
centre.10 One component is the DILIN Prospective Study, which is a prospective
observational study of patients with suspected DILI. This study is described in several
publications reporting study design,10 causality assessment,11 implicated medications,
clinical features and outcomes for the first 300 enrolled patients,12 and clinical
characteristics of drug-specific hepatotoxicity.13, 14
Here, we utilised a label-free quantitative proteomics approach (LFQP) to profile global
protein expression in serum samples from patients with idiosyncratic DILI enrolled in the
DILIN prospective study and healthy control subjects. LFQP is a high-throughput, sensitive
method for quantification of thousands of proteins in complex biological samples, including
serum.15 The objectives of this study were to: (i) describe differences in serum protein
expression among DILI patients based on hepatocellular, cholestatic, or mixed pattern of
liver injury, severity of liver injury (mild, moderate or severe/fatal), and causality
assessment (definite, very likely, probable, possible or unlikely), (ii) explore longitudinal
changes in serum protein expression over a 6-month recovery period in a subset of DILI
patients, (iii) identify differentially expressed serum proteins among patients with DILI vs.
controls, (iv) identify potential protein biomarkers of DILI with high discriminate ability and
(v) compare differentially expressed proteins identified in the current DILI study to those
identified in our previous serum proteomic analysis of patients across the spectrum of
nonalcoholic fatty liver disease (NAFLD).16
MATERIALS AND METHODS
Serum samples were obtained from a local blood bank (healthy controls) or were collected
as part of the DILIN prospective study, which was approved by the Institutional Review
Board at each academic clinical centre. As described,10 eligible patients with suspected DILI
provided written informed consent prior to their baseline study visit in which all previous
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medical data was reviewed with regard to inclusion/exclusion criteria and a complete history
and physical examination were performed. Patients were then enrolled if there was strong
suspicion that liver injury was caused by a prescription or over-the-counter medication or
dietary supplement/herbal product within the previous 6 months. Further laboratory testing
and data collection were also undertaken to fully characterise the DILI event and to exclude
underlying or competing aetiologies. All surviving participants were invited to return for a
6-month follow-up visit.
Inclusion/exclusion criteria
Eligibility for the DILIN prospective study included >2 years of age, a date of DILI onset
within the 6 months prior to enrolment and satisfaction of at least one of the following
biochemical criteria: (i) serum alanine aminotransferase (ALT) or aspartate aminotransferase
(AST) >5 times the upper limit of normal (ULN) or alkaline phosphatase >2 times the ULN
(or increases above pre-treatment baselines if liver biochemistries were elevated prior to
starting drug) on two consecutive occasions at least 2 days apart, (ii) total serum bilirubin
>2.5 mg/dL together with elevated AST, ALT or alkaline phosphatase or (iii) international
normalised ratio (INR) >1.5 together with elevated AST, ALT or alkaline phosphatase.
Patients with pre-existing liver conditions who developed superimposed DILI were
included. Patients with known or suspected acetaminophen toxicity or prior liver or bone
marrow transplant were excluded.
Clinical characterization of DILI and causality assessment
Type of liver injury was characterised by the R ratio [R = (ALT/ULN)/(alkaline
phosphatase/ULN)]1, 2: (i) R ≥ 5 was characterised as hepatocellular DILI, (ii) R ≤ 2 was
characterised as cholestatic DILI and (iii) R > 2 to R < 5 was characterised as mixed DILI.
As previously described,10 severity of DILI was graded as: (i) mild, (ii) moderate, (iii)
moderate-hospitalised, (iv) severe or (v) fatal. For the purposes of this study, patients with
moderate or moderate-hospitalised DILI were combined (moderate DILI) and patients with
severe or fatal DILI were combined (severe/fatal DILI). Causality was assessed by two
different methods as previously described10–12: (i) the Roussel Uclaf Causality Assessment
Method (RUCAM) and (ii) assignment of DILIN causality score based on unanimous
consensus of at least three DILIN Causality Committee members. Final causality was
categorised as: (i) definite (>95% likelihood), (ii) very likely (75–95%), (iii) probable (50–
74%), (iv) possible (25–49%) or (v) unlikely (<25%).
Sample preparation
All proteomic analyses were performed by the Protein Analysis Research Centre at Indiana
University School of Medicine. As previously described,15 samples were treated with
protease inhibitor cocktail (Sigma Aldrich, St. Louis, MO, USA) and protein extraction from
<100 μL serum was carried out in lysis buffer containing 8M urea and 10 mM dithiothreitol
(DTT). Fourteen high-abundance proteins were depleted by SepproTip columns (albumin,
IgG, alpha-1-antitrypsin, IgA, IgM, transferrin, haptoglobin, alpha-2-macroglobulin,
fibrinogen, complement C3, alpha-1-acid glycoprotein and apolipoproteins A-1, A-II and B)
and Bradford assay was used to determine protein concentrations.17 DTT, iodoacetamide,
triethylphosphine and iodoethanol were used to reduce and alkylate resulting protein
extracts.18 Protein mixtures were digested with trypsin and filtered through spin filters
before being applied to the high-performance liquid chromatography (HPLC) system.
Stability of the HPLC system and mass spectrometry (MS) instrument was evaluated by
spiking a constant amount of chicken lysozyme as an internal reference prior to tryptic
digestion of protein extracts.
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Liquid chromatography-tandem mass spectrometry (LC/MS/MS)
In random order, peptides (<20 μg) were injected onto an Agilent 1100 nano-HPLC system
(Agilent Technologies, Inc., Santa Clara, CA, USA) equipped with a C18 capillary column.
Peptides were eluted with a linear gradient from 5% to 45% acetonitrile developed at a flow
rate of 500 nL/min over 120 min. Effluent was electrosprayed into a LTQ mass spectrometer
(Thermo Fisher Scientific, Inc., Waltham, MA, USA). Acquired data were filtered and
analysed by a proprietary algorithm19 and database searches were carried out using the X!
Tandem 20 and SEQUEST21 algorithms against the International Protein Index (IPI) human
database (European Bioinformatics Institute, version 3.60) as previously described.22
Protein identification and quantification
Proteins were classified as priority one through four according to quality of peptide
identification (ID). ID confidence for each protein is greater with: (i) higher ID confidence
of individual peptides and (ii) a greater number of distinct amino acid sequences identified.
Priority 1 proteins have the greatest likelihood of correct identification (with multiple unique
peptide sequences identified) and priority 4 proteins have the least likelihood of correct
identification.
Quantification of proteins was carried out as previously described.19 Briefly, raw data files
were acquired from the MS instrument and all chromatograms were aligned according to
their retention time. After alignment, the area-under-the-curve for each individually aligned
peak was measured, normalised and compared for relative abundance.
Biostatistical analysis
Significant changes in protein expression among groups were detected by ANOVA (analysis of
variance). All data were normalised on a log2 scale (one unit difference is equivalent to a
two-fold change).23
From the ANOVA model a P-value, an estimate of the FPR (false positive rate), was obtained.
The P-value was modified to a q-value, which estimates the FDR (false discovery rate). The
q-value threshold was fixed to control the FDR at 5% (<0.05). A protein with ‘significant
change’ or ‘differential expression’ was defined as a difference in protein expression
between any two groups with a q-value <0.05.
Pathway and additional statistical analyses
For the main analysis and all subgroup analyses, all priority 1 proteins with significant
differential expression (q < 0.05) were considered for further characterization. Identified
proteins were classified according to biological function(s) using Ingenuity Pathway
Analysis software (https://analysis.ingenuity.com). Pearson’s correlation coefficient was
used to detect associations between liver biochemistries and expression of priority 1
proteins. When appropriate, stepwise regression analysis was performed to take into account
multiple independent variables (proteins) predicting the dependent variable (liver
biochemistries). Linear discriminant analysis and area-under-the-receiver-operating-curve
(AUROC) was used to determine the ability of individual proteins differentially expressed
between groups and patient characteristics to predict the presence of DILI vs. controls.
Statistical analyses were performed using JMP software (SAS Institute, Inc., Cary, NC,
USA). A P-value <0.05 was considered significant.
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A total of 114 subjects were included in this serum proteomic study. Characteristics of the
74 DILI patients (with a serum sample collected within 14 days of DILI onset) and 40
control subjects, including demographics and liver biochemistries, are shown in Table 1.
Implicated agents, regardless of causality assessment, are listed in Table 2. Overall, 2671
proteins were identified with the criteria we set for LFQP19, 22: 217 priority 1 proteins, 734
priority 2 proteins, 182 priority 3 proteins and 1538 priority 4 proteins.
In the DILI cohort, correlations between expression of differentially expressed priority 1
proteins and liver biochemistries were explored (Table 3). Interestingly, expression of
fumarylacetoacetase, an enzyme required for the breakdown of tyrosine, was associated with
ALT (r = 0.237; P = 0.047), AST (r = 0.389; P = 0.001) and alkaline phosphatase (r =
−0.240; P = 0.043). Fructose-bisphosphate aldolase B, a protein involved in carbohydrate
metabolism, was identified as an independent predictor of both ALT (r = 0.391; P = 0.001)
and AST (r = 0.523; P < 0.001). Apolipoproteins C-III (component of VLDL) and A-II
(component of HDL) were independently associated with alkaline phosphatase (r = 0.275; P
= 0.014) and bilirubin (r = −0.225; P = 0.05) levels respectively. Additional independent
predictors of bilirubin included proteins involved in extracellular matrix structure
[extracellular matrix protein 1 (isoform 1) (r = 0.229; P = 0.024)], iron metabolism and
antioxidant function [hemopexin (r = 0.494; P < 0.001)], and post-translational protein
modification [E3 SUMO-protein ligase RanBP2 (r = 0.265; P = 0.024)].
Pattern analysis: comparison of hepatocellular, cholestatic, or mixed liver injury
Within the DILI cohort, 45 patients (61%) were classified as having hepatocellular DILI, 15
patients (20%) hadcholestatic DILI, 11 patients (15%) had mixed DILI and three patients
(4%) were not classified by DILI type and were therefore not included in the pattern
analysis. We identified 25 differentially expressed (q < 0.05) proteins when comparing
patients with hepatocellular and cholestatic patterns of DILI (listed in Supplementary Table
S1). Expression of only one protein, fumarylacetoacetase, was different among patients with
hepatocellular and mixed DILI, and there were no differentially expressed proteins when
comparing the cholestatic and mixed DILI groups. Pattern analysis of the 25 priority 1
proteins differentially expressed between hepatocellular and cholestatic DILI patterns
showed involvement in mechanistic pathways implicated in DILI, including hepatotoxicity-
specific mechanisms of liver proliferation and development of cirrhosis (Figure 1).
Severity analysis: comparison of mild, moderate or severe/fatal liver injury
Mild (n = 9; 12%), moderate (n = 35; 47%) and severe/fatal (n = 19; 26%) DILI were all
well-represented in our cohort. Severity of DILI was not reported for 11 patients (15%), and
these subjects were excluded from this severity analysis. As shown in Supplementary Table
S2, expression of 29 priority 1 proteins was significantly different (q < 0.05) between the
mild and moderate DILI groups, 52 priority 1 proteins were differentially expressed between
the mild and severe/fatal DILI patients, and comparison of the moderate vs. severe/fatal
DILI groups revealed 23 priority 1 proteins with significant differential expression.
Expression of 9 priority 1 proteins was significantly different when comparing all three
severity groups: obscurin (isoform 1), polymeric immunoglobulin receptor, serine/threonine-
protein kinase 10, apolipoprotein A-II, transthyretin, macrophage colony-stimulating factor
1 receptor, complement component C7, vitamin D-binding protein and vitamin D-binding
protein precursor. Pattern analysis of these nine common proteins revealed involvement in
the acute phase response, activation of the complement cascade and peroxisome proliferator-
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activated receptor (PPAR)-α, and association with development of hepatocellular
carcinoma.
Causality assessment analysis: comparison of definite, very likely, probable, possible or
unlikely DILI
In our cohort of DILI patients, 17 were adjudicated as definite DILI (23%), 27 as very likely
DILI (36%), 8 as probable DILI (11%) and 11 as possible DILI (15%). Causality assessment
was not completed in seven cases (9%), and those patients were excluded from this causality
assessment analysis. Significant differential expression of priority 1 proteins was only
observed when comparing the definite and possible DILI groups (list of 12 proteins is shown
in Supplementary Table S3). Four subjects were deemed unlikely to have DILI and were
therefore classified as an ‘acute liver disease group.’ When these four patients were
compared with patients with DILI, no differentially expressed priority 1 proteins were
identified.
Longitudinal DILI analysis
Serum samples obtained within 14 days of DILI onset and after a 6-month follow-up period
were available for a subset of patients (n = 21; 28% of the DILI cohort), and clinical
characteristics and liver biochemistries of these patients are shown in Table 4. Expression of
53 priority 1 proteins changed significantly (q < 0.05) over the 6-month follow-up period
(Supplementary Table S4), and nearly all proteins trended back towards a ‘normal’
expression level (utilising the control group as a reference standard). As shown in Figure 2,
pathway analysis of these 53 proteins again revealed involvement in host immune response,
oxidative stress and hepatotoxicity-specific pathways including liver inflammation,
steatosis/steatohepatitis, necrosis/cell death and hepatitis.
Comparison of DILI patients and controls
Ninety-two priority 1 proteins were found to be differentially expressed (q < 0.05) between
the DILI and control groups (described in Supplementary Table S5). Pattern analysis of
these proteins revealed components of several mechanistic pathways, including
inflammation, acute phase proteins, complement system activation and coagulation (Figure
3; Panel A). In addition, several pathways directly related to hepatotoxicity (hepatic
inflammation, steatosis, cholestasis, necrosis/cell death and hepatitis) were represented in
the pattern analysis.
We assessed the ability of all priority 1 proteins differentially expressed between DILI
patients and controls (n = 92), along with patient characteristics (BMI and age) and liver
biochemistries (ALT, AST, alkaline phosphatase and bilirubin), to predict the presence of
DILI. As shown in Figure 3 (Panel B), apolipoprotein E had the greatest diagnostic ability
(89% of patients classified correctly; AUROC = 0.97) to distinguish DILI samples from
controls. When inter-alpha-trypsin inhibitor (heavy chain H3, isoform 1) was added, correct
patient classification increased to 91% (AUROC = 0.98). Addition of gelsolin (92% correct
classification; AUROC = 0.99) followed by complement component C7 (93% correct
classification; AUROC = 0.99), serum amyloid P component (95% correct classification;
AUROC = 0.99) and age (96% correct classification; AUROC = 0.99) all increased the
ability to predict DILI. The ability of ALT (73% correct classification; AUROC = 0.99)
(Figure 3; Panel B), AST (67% correct classification; AUROC = 0.99), alkaline phosphatase
(68% correct classification; AUROC = 0.96), bilirubin (77% correct classification; AUROC
= 0.94) or all four liver biochemistries combined (81% correct classification; AUROC =
0.99) to correctly classify patients with DILI vs. controls was also explored.
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Comparison with NAFLD proteomics
To identify potential nonspecific serum biomarkers of liver injury, we assessed overlap of
differentially expressed priority 1 proteins identified in both the present study of DILI
patients and healthy controls (92 priority 1 proteins) and in our previous serum proteomic
study of patients across the spectrum of NAFLD and obese controls (56 priority 1
proteins).16 Twenty-seven priority 1 proteins exhibited significant differential expression (q
< 0.05) compared with the respective control groups in both the DILI and NAFLD analyses,
and these proteins and their direction of change are listed in Supplementary Table S6.
DISCUSSION
There is an important need for increased understanding of the pathogenesis of DILI in
humans. Here, we describe results from a comprehensive serum proteomic analysis of
patients with DILI and controls. We observed significant differential expression of serum
proteins when comparing patients within the DILI group based on disease pattern, severity
and causality assessment and identified numerous differentially expressed proteins between
DILI patients and controls. In addition, strong associations between expression levels of
many priority 1 proteins and liver biochemistries were detected and 53 serum proteins that
changed significantly over a 6-month recovery period were identified. Pattern analysis of
differentially expressed proteins confirmed changes in protein expression related to
mechanistic pathways previously implicated in the pathogenesis of DILI, including
inflammatory and acute phase response, complement and coagulation system activation, and
oxidative stress.9, 24 In addition, proteins included in several hepatotoxicity-specific
pathways were identified, including liver inflammation, proliferation, steatosis/
steatohepatitis/hepatitis, cirrhosis, hepatocellular carcinoma and hepatocyte necrosis/death.
Large-scale ‘-omics’ technologies are powerful tools for molecular profiling of complex
disorders such as idi-osyncratic DILI. Conducted primarily in animal models of DILI,
various proteomic studies, often supplemented with metabonomic and transcriptomic
analyses, have revealed important information regarding prediction, detection, pathogenesis
and treatment of both acetaminophen-induced and idiosyncratic DILI.25–39 Of particular
relevance to the current proteomic study is a report by Andersson et al. describing
metabolomic and proteomic changes in serum samples from patients treated with
ximelagatran, which was associated with acute liver failure and was withdrawn from the
market in 2006.30 Novel biomarkers to predict predisposition to ALT elevation and
treatment response to ximelagatran were identified, including apolipoproteins A-II, A-IV
and E, and subsequent hypothesis-driven in vitro studies were carried out to confirm
previously unknown mechanisms of toxicity. In addition, Lewis et al. utilised an innovative
in vitro model system combined with a proteomic approach to identify intracellular and
extracellular proteins secreted into culture medium by a human hepatoma-derived cell line
(Hep G2/C3A) in response to ethanol toxicity.27 Interestingly, several differentially
expressed proteins identified in this model system were also detected in the current serum
proteomic study, including fructose-bisphosphate aldolase A, apolipoproteins A-I and E, and
multiple proteins involved in acute phase and inflammatory responses.
In the current study, interesting associations between expression of several identified serum
proteins and liver biochemistries were observed. For example, fumarylacetoacetase, an
enzyme predominantly expressed in the liver that is essential for tyrosine metabolism, was
significantly elevated in DILI patients compared with controls, correlated with ALT, AST
and alkaline phosphatase, and was also identified as the only priority 1 protein with
significantly higher expression in patients with hepatocellular vs. mixed pattern of injury.
Type I tyrosinaemia, a genetic disorder characterised by fumarylacetoacetase deficiency and
systemic accumulation of tyrosine, is strongly associated with liver failure and
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hepatocellular carcinoma.40 Indeed, the significant upregulation of fumarylacetoacetase
expression in patients with hepatocellular DILI suggests a compensatory mechanism in
response to accumulation of tyrosine and/or other toxic metabolites, including
fumarylacetoacetate, induced by hepatotoxic agents. Fructose-bisphosphate aldolase B, a
hepatic enzyme involved in glucose and fructose metabolism, was significantly greater in
patients with DILI compared with controls and in patients with hepatocellular DILI vs.
cholestatic DILI, and was identified as an independent correlate of both serum ALT and
AST elevations. Furthermore, fructose-bisphosphate aldolase B expression was significantly
elevated at baseline and expression returned to normal levels after 6 months in the
longitudinal analysis. These associations may provide an explanation for the previously
demonstrated detection of serum autoantibodies to fructose-bisphosphate aldolase B in
patients with troglitazone-induced hepatotoxicity41 and support the concept that expression
levels of this enzyme may correlate with extent of liver injury.
Identification of useful, noninvasive biomarkers of idiosyncratic DILI is complicated by the
fact that animal studies predict only approximately 50% of drugs that ultimately cause
hepatotoxicity in humans, and in vitro hepatocyte testing identifies 50–60% of compounds
that can induce liver injury in human clinical trials.42 In this serum proteomic study, we
identified elevations in apolipoprotein E, an abundant apolipoprotein constituent of
triglyceride-rich chylomicrons and intermediate-density lipoproteins, as having the greatest
diagnostic power for differentiating patients with DILI from controls. Interestingly, Ferre et
al. demonstrated that apolipoprotein E-deficient mice exhibited worse liver injury upon
carbon tetrachloride challenge compared with wild-type mice.43 Inclusion of expression of
additional proteins involved in inflammation [inter-alpha-trypsin inhibitor (heavy chain H3,
isoform 1) and serum amyloid P-component], mitochondrial stabilisation and apoptosis
(gelsolin), and the innate immune response (complement component C7 and serum amyloid
P-component) increased our ability to predict the presence of DILI. These findings are
consistent with the response of hepatocytes and other cell types residing in the liver to drug-
induced injury, which involves systemic release of cytokines and other factors implicated in
various inflammatory and immunity pathways.24
Although this study was the first to explore the global serum proteome of patients with
idiosyncratic DILI, there are several limitations that require mention. First, although
distinguishing DILI patients from healthy control subjects is interesting from a pathogenetic
stand-point, this approach is not highly relevant in a clinical setting. Rather, identification of
biomarkers for rapid differentiation of patients with DILI from those with other acute liver
diseases is an important unmet clinical need. We were unable to assess this issue as the
current study included only a small group of patients with acute liver injury thought unlikely
to be due to DILI (n = 4). Second, a concern with multiple serum proteomic studies
involving different liver diseases is the possibility of identification of nonspecific markers of
hepatic injury. We compared findings from the current proteomic study in DILI patients and
healthy controls to data generated from our previous discovery proteomic study in patients
across the spectrum of NAFLD and obese controls.16 Of the 92 and 56 differentially
expressed priority 1 proteins identified in the DILI and NAFLD analyses respectively, only
27 common proteins were identified and may serve as general biomarkers of liver injury.
Importantly, apolipoprotein E, which was identified as having the greatest ability to
differentiate DILI patients from controls, was not differentially expressed in the NAFLD
proteomic analyses. This protein, along with the additional 65 proteins with significant
differential expression unique to the DILI analysis, may serve as candidate biomarkers for
identification of DILI. Third, we were unable to assess changes in serum protein expression
with regard to individual medications/supplements due to the large number of agents and
small numbers of patients exposed to individual drugs. Finally, prediction of individuals
who will go on to develop hepatotoxicity prior to drug exposure would be an invaluable tool
Bell et al. Page 8













for drug development and improved patient safety. This type of analysis requires serum
samples taken prior to DILI onset, which are not available as part of the DILIN prospective
registry. Despite these limitations, our study provides novel insight into changes in the
serum proteome in patients with idiosyncratic drug-induced hepatotoxicity and provides a
foundation for future hypothesis-driven studies that may aid in prevention, early detection,
clarification of pathogenesis and effective treatment modalities for DILI.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Pathway analysis of priority 1 proteins with significant differential expression when
comparing DILI patients with hepatocellular and cholestatic patterns of liver injury.
Classification of the 25 priority 1 proteins with significant (q < 0.05) differential expression
when comparing patients with hepatocellular and cholestatic DILI demonstrated
involvement in inflammatory and immune system response pathways, activation of the
coagulation cascade and included proteins previously implicated in liver proliferation and
development of cirrhosis.
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Pathway analysis of priority 1 proteins with significant differential expression when
comparing baseline and 6-month follow-up samples from patients with DILI included in the
longitudinal analysis. Classification of the 53 priority 1 proteins with significant (q < 0.05)
differential expression when comparing patients with DILI at baseline (within 14 days of
DILI onset) and after a 6-month follow-up period revealed proteins with functions related to
inflammation and oxidative stress, including those involved in liver steatosis/steatohepatitis/
hepatitis and hepatocyte necrosis/cell death. Expression of nearly all differentially expressed
proteins returned to ‘normal’ expression levels throughout the 6-month follow-up period
(using protein expression in the control group as a reference standard).
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Pathway analysis of priority 1 proteins differentially expressed between DILI patients and
controls and identification of proteins with the greatest ability to differentiate patients with
DILI vs. controls. Ingenuity Pathway Analysis software was used to classify the 92 priority
1 proteins with significant (q < 0.05) differential expression when comparing DILI patients
and controls (Panel A), and pattern analysis showed involvement in many pathways
previously implicated in the pathogenesis of DILI, including several directly related to
hepatotoxicity (liver inflammation, steatosis, cholestasis, necrosis/cell death, and hepatitis).
Diagnostic power of priority 1 proteins and clinical characteristics was explored by linear
discriminant analysis and assessment of AUROC (Panel B; grey bars). Apolipoprotein E
was identified as having the greatest power to differentiate DILI patients and controls (89%
of patients classified correctly; AUROC = 0.97), and consideration of expression of several
additional proteins and age increased the percentage of patients classified correctly to 96%
and the AUROC to 0.99. The diagnostic utility of ALT alone (black bar) in differentiating
patients from controls is also shown (73% correct classification; AUROC = 0.99).
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Table 1






Age, mean ± s.d. (years) 47.8 ± 18.3 49.2 ± 13.1
Female (%) 53 28
Self-reported race (%)
  White 72 95
  Black 11 5
  Others 16 0
  Unknown 1 0
Body mass index,
 mean ± s.d. (kg/m2)
27.0 ± 6.6 30.5 ± 6.9




Prior drug allergies (%) 50
Diabetes mellitus (%) 34
Liver biochemistries, mean ± s.d.
  ALT (U/L) 1086 ±1409 17.4 ± 5.1
  AST (U/L) 1028 ± 1274 24.3 ± 4.9
Alkaline phosphatase
  (U/L)
325.3 ± 470.1 63.2 ± 14.0
 Total bilirubin (mg/dL) 8.0 ± 7.6 0.6 ± 0.2
 INR 1.8 ± 1.2
Absolute eosinophils/iL
 (mean ± s.d.)
172.3 ± 240.2
Pattern of liver injury (%)
  Hepatocellular 61
  Cholestatic 20
  Mixed 15
  Unknown 4
Severity of liver injury (%)
  Mild 12
  Moderate 47
  Severe/fatal 26
  Unknown 15
Causality score (%)
  Definite 23
  Very likely 36
  Probable 11



















  Possible 15
  Unknown 15
Implicated agents (%)
  Single prescribed agent 57
  Single dietary agent 5




Chronic DILI (%) 5
Liver-related mortality (%) 5
Liver transplantation (%) 0
ALT, alanine aminotransferase; AST, aspartate aminotransferase; DILI, drug-induced liver injury; INR, international normalised ratio; s.d.,
standard deviation.
*
Pre-existing liver conditions included hepatitis C, hepatitis B, alcoholic liver disease and nonalcoholic fatty liver disease.
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Table 2
Implicated causative agents
Single agent Multiple agents
(n = 1 case each)
Isoniazid (n = 5) Moxifloxacin + ciprofloxacin
 + amoxicillin/clavulanate
Herbal preparation (n = 5) Pregabalin + simvastatin
 + mercaptopurine
Amoxicillin/




Nitrofurantoin (n = 3) Trimethoprim-
 sulfamethoxazole
 + orlistat
Methyldopa (n = 2) Metoprolol + diltiazem
 + alprazolam
Minocycline (n = 2) Isoflurane + lorazepam
 + clindamycin
Trimethoprim-




Amiodarone (n = 1) Phenytoin + levofloxacin
 + phenobarbital
Amlodipine (n = 1) Isoniazid + rifampicin
Anabolic steroid (n = 1) Ciprofloxacin + metronidazole
Antithymocite
 immunoglobulin (n = 1)
Amitriptyline + nicotinic acid
Atorvastatin (n = 1) Allopurinol + rosiglitazone
Atripla (n = 1) Vincristine + asparaginase
Azathioprine (n = 1) Ceftriaxone + ampicillin/
 sulbactam + fluconazole
Azithromycin (n = 1) Flavocoxid + pregabalin
Bortezomib (n = 1) Amoxicillin/clavulanate
 + valproic acid + amiodarone
Chlorzoxazone (n = 1) Methyldopa + labetalol
Drospirenone/
 ethinylestradiol (n = 1)
Dicloxacillin +
 amoxicillin/clavulanate
Duloxetine (n = 1) Nicotinic acid + neomycin
Fenofibrate (n = 1) Lamotrigine + ziprasidone
Investigational drug (n = 1) Lamotrigine + valproic acid
Lamotrigine (n = 1) Disulfiram + lisinopril
Nicotinic Acid (n = 1) Allopurinol + fluconazole
 + cyclophosphamide
Octreotide (n = 1) Carbamazapine + bactrim
 + lisinopril
Oxacillin (n = 1) Metformin + fenofibrate
Phenylpropanolamine (n = 1) Voriconazole + fluconazole
Phenytoin (n = 1)
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Single agent Multiple agents
(n = 1 case each)
Pregabalin (n = 1)
Rifabutin (n = 1)
Sertraline (n = 1)
Simvastatin (n = 1)
Telithromycin (n = 1)
Valaciclovir (n = 1)
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Table 3
Correlative analyses of priority 1 protein expression and liver biochemistries in the DILI cohort
Liver
biochemistry
Positive correlates Negative correlates
Protein rho (95% CI) P-value Protein rho (95% CI) P-value
ALT alpha-1-antitrypsin (isoform 1) 0.250 (0.018, 0.457) 0.036
PR02275 0.246 (0.013, 0.453) 0.039
Fructose-bisphosphate aldolase B* 0.391 (0.173, 0.572) 0.001
Fumarylacetoacetase 0.237 (0.003, 0.445) 0.047
AST alpha-1-antitrypsin (isoform 1) 0.329 (0.107, 0.520) 0.005 Transthyretin −0.249 (−0.453,−0.020) 0.034
PR02275 0.334 (0.112, 0.524) 0.004
C-reactive protein (isoform 1) 0.300 (0.075, 0.496) 0.0
Leucine-rich alpha-2-glycoprotein 0.239 (0.010, 0.445) 0.041
Fructose-bisphosphate aldolase B* 0.523 (0.333, 0.672) <0.001
Fumarylacetoacetase 0.389 (0.174, 0.568) 0.001
Serpin A11 0.302 (0.078, 0.498) 0.009
DNA-directed RNA polymerase I
 subunit RPA1
0.290 (0.064, 0.487) 0.013
Obscurin (isoform 1) 0.335 (0.114, 0.525) 0.004
alpha-skeletal muscle actin 0.252 (0.023, 0.456) 0.032





0.342 (0.120, 0.532) 0.003 Fumarylacetoacetase −0.240 (−0.446, −0.008) 0.043
Serum amyloid A2 (isoform a) 0.238 (0.006, 0.445) 0.044
Apolipoprotein C-III* 0.322 (0.098, 0.515) 0.006
Total Bilirubin Apolipoprotein E 0.280 (0.051, 0.480) 0.017
Polymeric immunoglobulin receptor 0.391 (0.175, 0.571) 0.001 Apolipoprotein A-II* −0.503 (−0.658, −0.308) <0.001
von Willebrand factor 0.325 (0.101, 0.518) 0.005 Apolipoprotein A-I −0.391 (−0.571, −0.176) 0.001
Aminoacylase-1 0.240 (0.008, 0.446) 0.043 G-protein coupled
 receptor 98 (isoform 1)
−0.488 (−0.647, −0.289) <0.001
Fructose-bisphosphate aldolase A 0.261 (0.032, 0.465) 0.027 Paraoxonase/arylesterase 1 −0.282 (−0.482, −0.053) 0.017
Complement component C7 0.249 (0.019, 0.455) 0.035 Hemopexin* −0.494 (−0.651,−0.296) <0.001
Complement C1q subcomponent
 (subunit A)
0.308 (0.082, 0.504) 0.009 Paraoxonase/lactonase 3 −0.251 (−0.456, −0.021) 0.033
Complement C2 (fragment) 0.389 (0.172, 0.569) 0.001 Versican core protein
(isoform Vint)
−0.255 (−0.460,−0.025) 0.031
Extracellular matrix protein 1
 (isoform 1)*
0.314 (0.089, 0.509) 0.007 E3 SUMO-protein ligase
RanBP2*
−0.265 (−0.468, −0.036) 0.024
Obscurin (isoform 1) 0.310 (0.084, 0.505) 0.008 Haptoglobin-related
 protein (isoform 1)
−0.237 (−0.444,−0.005) 0.046
Adiponectin 0.312 (0.086, 0.507) 0.008 Haptoglobin −0.238 (−0.445, −0.007) 0.044
Tetranectin 0.252 (0.022, 0.457) 0.033
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Liver
biochemistry
Positive correlates Negative correlates
Protein rho (95% CI) P-value Protein rho (95% CI) P-value
Uncharacterized protein
 DKFZp686C02220 (fragment)
0.345 (0.123, 0.534) 0.003
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; rho, Pearson’s correlation coefficient.
*
Independent predictor upon multivariate regression analysis.
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Table 4
Clinical characteristics and liver biochemistries of study participants included in the longitudinal analysis
DILI Cohort
(n = 21)







Body mass index, mean ± s.d. (kg/m2) 27.5 ± 7.7
Alcohol use (%) 52
Preexisting liver disease (%) 14
Prior drug allergies (%) 48
Diabetes mellitus (%) 43
Liver biochemistries, mean ± s.d.
 ALT (U/L)
  Baseline 1325 ± 2139
  6-month visit 36.1 ± 16.5
 AST (U/L)
  Baseline 1141 ± 1696
  6-month visit 32.6 ± 11.4
 Alkaline phosphatase (U/L)
  Baseline 219.9 ± 161.0
  6-month visit 87.2 ± 31.2
 Total bilirubin (mg/dL)
  Baseline 9.8 ± 9.0
  6-month visit 0.9 ± 0.7
 INR
  Baseline 1.9 ± 1.0
  6-month visit 1.1 ± 0.5
Absolute eosinophils/μL (mean ± s.d.)
 Baseline 129.7 ± 132.6
 6-month visit 122.2 ± 115.5
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DILI Cohort
(n = 21)












 Single prescribed agent 57
 Single dietary agent 10
 Multiple prescribed agents 33
 Unknown 0
Chronic DILI (%) 0
Liver-related mortality (%) 0
Liver transplantation (%) 0
DILI, drug-induced liver injury; s.d., standard deviation; ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, international
normalised ratio.
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